AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Consequently, the early literature reporting cataract surgery routinely documented the mortality rate (secondary to pulmonary emboli ... is focused on the retina. These complex lenses are ...
Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Systematic evaluation of neuro-ophthalmic outcomes of the ophthalmic artery covered by flow-diverter
The study revealed that, through comprehensive ophthalmic examinations, 5 patients (17.9%) experienced retinal embolism, with 4 of these cases falling under Type A. Moreover, the incidence of ...
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...
A left ventricular thrombus following a heart attack is considered a very serious complication because of the risk the clot will travel to the brain and cause a stroke or a systemic embolism.
AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback